MyMD Pharmaceuticals, Inc. MyMD Pharmaceuticals Inc – Stock Price, Quote and News (” MyMD” or “the Company”), a professional phase pharmaceutical firm dedicated to extending healthy and balanced life-span, today revealed that the first client has been signed up in the Firm’s Phase 2 scientific test of lead candidate MYMD-1, an oral immune regulator drug, as a therapy for delaying aging and also expanding healthy life expectancy.
The key endpoint for the Stage 2 double-blind, placebo-controlled clinical test is to accomplish a decrease in the flowing degrees of (TNF-α), growth death factor receptor I (TNFRI) as well as IL-6. TNF-α and IL-6 are the proteins in the body that cause inflammation and also help activate the process of aging. The second measures of the test will certainly be the safety, tolerability, and also pharmacokinetics in this population of individuals.
” In a Stage 1 medical trial of MYMD-1, we showed the drug’s statistically significant efficacy in minimizing degrees of TNF-α, a key player in creating pathological aging, in the blood. The FDA has approved TNF-α reduction as the primary endpoint for our Stage 2 research, which our company believe placements us well for a successful Phase 2 result,” said Chris Chapman, M.D., Head Of State, Director and Chief Medical Officer of MyMD. “The initiation of individual enrollment in this research study advancements our mission to slow down the aging process, avoid loss of muscle mass cells in aging, limit frailty, and also extend healthy life expectancy.”
MyMD has actually specified that there are no FDA-approved drugs for treating aging conditions as well as prolonging healthy and balanced life expectancy people, a market expected to be at the very least $600 billion by 20251 according to a significant investment financial institution. TNF-α blockers are one of the most recommended medications by revenue, a global market of about $40 billion each year,2 and also, according to Nature Aging journal,3 a stagnation in maturing that would certainly enhance life span by one year deserves $38 trillion and also by ten years is worth $367 trillion.
In addition to aging, MYMD-1’s distinctive action in managing the body immune system as well as dealing with persistent swelling is being created for the therapy of autoimmune condition, including rheumatoid joint inflammation (RA), numerous sclerosis (MS), diabetes, and inflammatory digestive tract condition.
” We plan to begin writing methods for a Phase 2 pilot research study of MYMD-1 for rheumatoid arthritis early this year,” Dr. Chapman kept in mind. “The climbing frequency of rheumatoid joint inflammation and other autoimmune and inflammatory illness are driving demand for TNF preventions like MYMD-1, and also our team believe our by mouth provided drug with really low poisoning would be turbulent to the $60 billion market for RA if authorized by the FDA for this indicator.”
Rheumatoid arthritis impacts about 40 million people around the world.4.
Originally created for autoimmune diseases, MYMD-1’s key purpose is to slow down the aging procedure, prevent sarcopenia and frailty, and extend healthy lifespan. Since it can go across the blood-brain barrier and also access to the main nervous system (CNS), MYMD-1 is additionally placed to be a feasible therapy for brain-related problems. Its system of activity and efficiency in conditions consisting of numerous sclerosis (MS) as well as thyroiditis have actually been examined with partnerships with several academic organizations. MYMD-1 is likewise showing pledge in pre-clinical studies as a potential therapy for blog post- COVID-19 issues and also as an anti-fibrotic and also anti-proliferation healing.
MYMD-1 has actually revealed efficiency in pre-clinical researches in controling the body immune system by executing as a careful inhibitor of lump necrosis factor-alpha (TNF-α), a motorist of persistent swelling. Unlike other therapies, MYMD-1 has been received these pre-clinical researches to selectively block TNF-α when it becomes overactivated in autoimmune diseases as well as cytokine tornados, however not block it from doing its normal work of being a first -responder to any kind of routine sort of modest infection. MYMD-1’s convenience of oral dosing is another differentiator contrasted to currently available TNF-α blockers, every one of which need shipment by shot or infusion. No approved TNF prevention has actually ever before been dosed by mouth. On top of that, the medication is not immunosuppressive and has actually not been revealed to create the major adverse effects common with conventional therapies that treat swelling.
Regarding MyMD Pharmaceuticals, Inc
. MyMD Pharmaceuticals, Inc. (Nasdaq: MYMD), a professional phase pharmaceutical firm dedicated to expanding healthy life-span, is concentrated on establishing 2 unique therapeutic platforms that treat the root causes of illness instead of just resolving the signs. MYMD-1 is a medication system based upon a clinical stage tiny particle that manages the immune system to control TNF-α, which drives chronic inflammation, as well as other pro-inflammatory cell signaling cytokines. MYMD-1 is being created to delay aging, increase durability, and treat autoimmune conditions and COVID-19- associated clinical depression. The Firm’s second drug platform, Supera-CBD, is being established to deal with chronic discomfort, dependency and also epilepsy. Supera-CBD is a novel synthetic derivative of cannabidiol (CBD) and also is being developed to deal with as well as improve upon the swiftly growing CBD market, that includes both FDA accepted medicines as well as CBD items not currently controlled as drugs. To find out more, see www.mymd.com.